Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Cancers
|
May 28, 2022
<i>BRCA</i>-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, et al.
JCO Oncology Practice
|
April 7, 2021
Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems
Divya A Parikh, Meera Ragavan, Ritika Dutta, et al.
Translational Oncology
|
April 22, 2014
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers
Julie Bauman, Monte Shaheen, Claire F Verschraegen, et al.
American Journal of Clinical Oncology
|
December 29, 2015
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma
Steven J Cohen, Mark M Zalupski, Paul Conkling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R Parikh, Fa-Chyi Lee, Linda Yau, et al.
Cancer Medicine
|
August 13, 2017
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
Yehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, et al.
Cancer
|
November 30, 2006
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
Heinz-Joseph Lenz, Fa-Chyi Lee, Daniel G Haller, et al.
American Journal of Clinical Oncology
|
September 1, 2007
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results
Yehuda Z Patt, Fa-Chyi Lee, James E Liebmann, et al.
The Oncologist
|
November 22, 2017
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Emilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
Jaffer A Ajani, Fa-Chyi Lee, Deepti A Singh, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Cancers
|
May 28, 2022
<i>BRCA</i>-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
Naomie Devico Marciano, Gianna Kroening, Farshid Dayyani, et al.
JCO Oncology Practice
|
April 7, 2021
Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems
Divya A Parikh, Meera Ragavan, Ritika Dutta, et al.
Translational Oncology
|
April 22, 2014
A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers
Julie Bauman, Monte Shaheen, Claire F Verschraegen, et al.
American Journal of Clinical Oncology
|
December 29, 2015
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma
Steven J Cohen, Mark M Zalupski, Paul Conkling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R Parikh, Fa-Chyi Lee, Linda Yau, et al.
Cancer Medicine
|
August 13, 2017
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
Yehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, et al.
Cancer
|
November 30, 2006
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study
Heinz-Joseph Lenz, Fa-Chyi Lee, Daniel G Haller, et al.
American Journal of Clinical Oncology
|
September 1, 2007
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results
Yehuda Z Patt, Fa-Chyi Lee, James E Liebmann, et al.
The Oncologist
|
November 22, 2017
Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Emilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2006
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma
Jaffer A Ajani, Fa-Chyi Lee, Deepti A Singh, et al.
Page
of 4